title: Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?
authors.affiliation: Gastroenterology Department, St. Vincent's Hospital, Melbourne, Victoria, Australia. alexander.thompson@svhm.org.au
authors.forename: Alexander J
authors.initials: AJ
authors.lastname: Thompson
authors.forename: John G
authors.initials: JG
authors.lastname: McHutchison
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D004279:DNA, Viral / Q000032:analysis / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016503:Drug Delivery Systems; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage; D011110:Polymorphism, Genetic; D011392:Proline / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D007372:Interferons; D007378:Interleukins; D009842:Oligopeptides; D011392:Proline; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide